Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: cerebrovascular
- Who it enrolls
- age 18 Years to no upper limit; excludes diabetes; no BMI minimum stated; conditions: Acute Ischemic Stroke
- Interventions
- Semaglutide; Standard care
- Conditions
- Acute Ischemic Stroke
- Phase and size
- Phase 2 · 380 participants
- Dates
- Start 2023-04-12
Primary completion 2025-09 - Sponsor
- Aarhus University Hospital (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Modified Ranking Scale90 (+/- 14) days
02Eligibility
Who can take part
Inclusion Criteria: * Male and female patients (≥ 18 years) at the time of signed informed consent/proxy consent * Acute ischemic stroke with disabling neurological deficits (defined as an impairment of one or more of the following: language, motor function, cognition, gaze, vision, neglect, or ataxia) * Onset/last seen well to randomization \< 4.5 hours * None to moderate disability in daily living before symptom onset (pre-stroke modified Rankin Scale 0-3) Exclusion Criteria: * Diabetes (known) or plasma/point of care test-glucose \>11.1 mmol/L at admission * BMI\< 22 * History of pancreatitis, medullary thyroid carcinoma * Predisposition or known Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) * Short remaining life expectancy (\< 12months) and/or severe neurodegenerative disease * Pregnancy or planned pregnancy within 12 months or breastfeeding * Renal impairment measured as estimated glomerular filtration rate (eGFR) value of \<30 mL/min/1.73 m2
03Change log
Registry changes
No changes recorded since the trial was added.